Hims & Hers Officer Plans $143k Stock Sale Under 10b5-1 Plan
Hims & Hers Health, Inc.
Subscribe to track HIMS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Hims & Hers Officer Plans $143k Stock Sale Under 10b5-1 Plan
Company: Hims & Hers Health, Inc. Form: 144 | Filed: 2025-10-14 Significance: Low
Insider: Boughton Soleil Title: null | Relationship: Officer
Transaction (Proposed): • Type: Proposed Sale • Shares: 2,637 • Approx. Value: $143,400.06 • Approx. Price: $54.38
Key Insight: This is a notice of a proposed sale, not a completed one. The sale is part of a pre-arranged 10b5-1 trading plan adopted in August 2024, which significantly reduces its informational value as it's a planned liquidation, not a reaction to recent events.
Market Context: The filing discloses a consistent pattern of similar sales over the past three months, reinforcing the interpretation of a scheduled, programmatic selling plan.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Hims & Hers Health, Inc.
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer at Hims & Hers Health, Inc. has filed a notice of a proposed sale of 2,637 shares valued at approximately $143,400. The sale is planned under a Rule 10b5-1 trading plan, indicating it is a pre-scheduled transaction rather than a spontaneous decision based on current company prospects.
- Market Impact: The market impact is expected to be neutral to minimal. Sales under 10b5-1 plans are common for executive compensation and diversification and are generally not interpreted as a bearish signal by sophisticated investors.
Company Information
| Field | Value |
|---|---|
| Company | Hims & Hers Health, Inc. |
| Ticker Symbol | null |
| CIK | 0001773751 |
| Industry | Services-Offices & Clinics of Doctors of Medicine |
Insider Information
| Field | Value |
|---|---|
| Name | Boughton Soleil |
| CIK | 0001837817 |
| Title/Position | null |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Transaction Date | 2025-10-13 (Approximate) |
| Transaction Code | null |
| Security Type | Class A |
| Shares Involved | 2,637 |
| Price Per Share | $54.38 (Approximate) |
| Total Value | $143,400.06 |
| Shares Owned After | Not specified |
| Ownership Type | Not specified |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Form 144 filings for sales under a 10b5-1 plan are routine disclosures. The pre-planned nature of the transaction, established in August 2024, strips it of most signaling value regarding the insider's current outlook on the company.
Volume & Sentiment
- Expected Volume Impact: Negligible. The size of the proposed sale is very small relative to the company's total outstanding shares (217,641,958) and typical daily trading volume.
- Sentiment Indicator: Neutral. While any insider sale could be viewed as bearish in isolation, the context of a 10b5-1 plan and a history of regular, similar-sized sales neutralizes this sentiment.
Investment Insights
Positive Market Indicators
- The use of a 10b5-1 plan demonstrates a structured and compliant approach to insider stock sales.
Risk Factors
- A consistent pattern of insider selling, even if planned, can sometimes create a slight headwind for a stock if not understood correctly by the market.
Key Takeaways
- Planned Liquidation: This is a pre-scheduled sale, not an opportunistic trade. The decision to sell was made when the plan was adopted on August 28, 2024.
- Pattern of Sales: The filing details six prior sales in the last three months, confirming a regular, programmatic selling schedule by the insider.
- Low Informational Value: Due to the planned nature and relatively small size of the transaction, this filing provides little to no new information about the company's future performance.
Contextual Analysis
Timing Significance
- The filing is a notice of intent to sell around October 13, 2025. The key date is the plan adoption date (August 28, 2024), which long precedes the transaction, minimizing the significance of the sale's timing.
Transaction Context
- The securities were acquired on September 15, 2025, through 'Restricted Stock Vesting' as part of compensation. This sale is a common way for executives to liquidate vested shares to cover taxes or for personal financial planning.
Company Context
- Hims & Hers Health, Inc. operates in the telehealth and wellness industry. Analysis of this filing should be paired with a broader look at the company's recent earnings reports, product pipeline, and competitive landscape.
Risk Assessment
Risk Level: Low
Risk Factors
- Misinterpretation: The primary risk is for uninformed investors to misinterpret this routine, planned sale as a bearish signal from the insider.
- Selling Pressure: While this single transaction is immaterial, the aggregate of all insider and institutional selling could create technical pressure on the stock price.
Market Considerations
- 10b5-1 Plans: These plans are a standard tool for insiders to sell shares in an orderly manner without facing accusations of trading on non-public information.
- Vesting Schedules: Sales often follow vesting dates as insiders convert equity compensation into cash.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-14 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.